Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Change in Account Payables: 2015-2024

Historic Change in Account Payables for Intellia Therapeutics (NTLA) over the last 10 years, with Dec 2024 value amounting to $6.8 million.

  • Intellia Therapeutics' Change in Account Payables rose 162.30% to $3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $464,000, marking a year-over-year decrease of 95.01%. This contributed to the annual value of $6.8 million for FY2024, which is 169.63% up from last year.
  • Intellia Therapeutics' Change in Account Payables amounted to $6.8 million in FY2024, which was up 169.63% from $2.5 million recorded in FY2023.
  • In the past 5 years, Intellia Therapeutics' Change in Account Payables registered a high of $6.8 million during FY2024, and its lowest value of -$4.6 million during FY2022.
  • Its 3-year average for Change in Account Payables is $1.6 million, with a median of $2.5 million in 2023.
  • As far as peak fluctuations go, Intellia Therapeutics' Change in Account Payables tumbled by 966.54% in 2022, and later spiked by 169.63% in 2024.
  • Intellia Therapeutics' Change in Account Payables (Yearly) stood at $5.1 million in 2020, then slumped by 89.55% to $529,000 in 2021, then plummeted by 966.54% to -$4.6 million in 2022, then skyrocketed by 155.02% to $2.5 million in 2023, then soared by 169.63% to $6.8 million in 2024.